Skip to content
Screener

Supernus Pharmaceuticals SUPN EBITDA

EBITDA at other companies

AbbVie logo
AbbVieABBV
$5.93B+2.7%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$60.59M-107%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$40.99M+16.1%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$47.91M-36.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$200.7M+543%
XER
Xeris Biopharma Holdings, Inc.XERS
$5.5M+14.3%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.77B+21.8%
Enterprise value$2.63B+21.5%
P/S3.6×+0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Calculated from Supernus Pharmaceuticals’s reported figures.

−$8.3Mebit+
$26.1MDepreciation Depletion & Amortization
=$17.8M

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022

FAQ

What is Supernus Pharmaceuticals's EBITDA?
Supernus Pharmaceuticals (SUPN) reported EBITDA of $17.8M in Q1 2026.
How has Supernus Pharmaceuticals's EBITDA changed year-over-year?
Supernus Pharmaceuticals's EBITDA increased by 75.8% year-over-year, from $10.13M to $17.8M.
What is the long-term trend for Supernus Pharmaceuticals's EBITDA?
Over 4 years (2021 to 2025), Supernus Pharmaceuticals's EBITDA has grown at a -29.5% compound annual growth rate (CAGR), from $118.62M to $29.28M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Supernus Pharmaceuticals's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude